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UltrasoundAbstract Background: Delayed resolving pneumonia represents a perplexing diagnostic dilemma.
Many methods can lend a hand in diagnosis; however prediction of such a problem wishes a more
precision.
Objectives: Deﬁne to what extent early anticipation of underlying causes of delayed resolving
pneumonia via clinical, radiological and bronchoscopic markers would modify management plan
and affect their outcomes.
Patients and methods: Prospective clinical study was conducted on 122 patients with delayed
resolving pneumonia. They underwent chest X-ray, thoracic ultrasound, chest computed tomogra-
phy (CT) and ﬁberoptic bronchoscopy (FOB). Tissue biopsy was taken for pathological examina-
tion.
Results: Studied cases were divided into two groups: group I included 58 patients with malignant
etiology (49 cases with lung cancer and 9 cases with pulmonary metastasis) and group II included 64
patients with nonmalignant etiology (nonspeciﬁc pneumonia in 42 cases, speciﬁc forms of pneumo-
nia in 14 cases, pulmonary sequestration in 4 cases and traction bronchiectasis in 4 cases). Sensitiv-
ity of clinical and CT chest markers of malignancy was 72.36% and 53.45% respectively however
their speciﬁcities were 20.62% and 59.38% respectively. Thoracic ultrasound showed the highest
sensitivity (75.86%) but lowest speciﬁcity (17.19%). FOB markers of malignancy were signiﬁcantly
higher in malignant than the non-malignant group (p= 0.001). Summation of clinical, FOB, CT
chest and sonographic markers increased the probability of malignancy in 67.2% and excluded
malignancy in 71.8% of cases with a success rate of 69.7%.
Conclusion: Early anticipation of what beyond delayed resolution of pneumonia can assist in
earlier veriﬁcation of causes and supervising course and guard against consequences.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.Introduction
Pneumonia which resolves slowly after appropriate antibiotic
therapy can be problematic. Richard Winterbauer et al. had
empirically deﬁned slowly resolving pneumonia ind.
138 A.M. Abumossalam et al.immunocompetent patients as either less than 50% radiologi-
cal clearing at 2 weeks or less than complete clearance at
4 weeks in a patient who has defervesced and symptomatically
improved with antibiotic therapy [1]. Normal resolution of
pneumonia is not easily deﬁned. It can vary depending on
the infecting organism and the host immune status. Patients
typically note subjective improvement within 3–5 days of initi-
ation of treatment. Knowledge about factors causing nonreso-
lution, will help to avoid unnecessary invasive diagnostic
procedures [2].
The expected time of radiographic resolution is inﬂuenced
by both host factors and the culprit pathogen. In a later
review, Fein and Feinsilver [3] deﬁned ‘‘a minimum of 10 days
of antibiotic therapy and a radiographic inﬁltrate that is not
resolving in an ‘expected’ period of time based on the pre-
sumed diagnosis. These criteria are admittedly arbitrary and
lack precision. Nonetheless, in some patients, delayed radio-
graphic resolution reﬂects derangements in host defenses,
obstructing endobronchial lesions, pulmonary malignancies,
metastatic pulmonary process or myriad alternative causes
(both infectious and noninfectious). When patients with sus-
pected pneumonia fail to improve within the expected time
frame or deteriorate, alternative causes or factors contributing
to delayed resolution must be assessed [4].
One must ask whether the antibiotic is inappropriate
(because of antimicrobial resistance; inadequate bioavailabil-
ity, penetration, or pharmacokinetics; noncompliance). Has a
sequestered site of infection been overlooked (e.g., abscess
and empyema)? Is failure related to impaired immune or host
defenses? Are nonbacterial causes possible (e.g., viruses, fungi,
mycobacteria and protozoans)? Noninvasive (e.g., serologic)
and invasive (e.g., bronchoscopy) techniques are useful in
establishing a speciﬁc diagnosis [5]. Noninvasive studies may
include serologies or urinary antigen assays for Legionella
[6]. Tuberculin skin testing and sputum smears and cultures
for acid-fast bacteria may be indicated in patients with risk fac-
tors or clinical features suggestive ofMycobacterium tuberculo-
sis [7]. Epidemiologic clues (e.g., travel history, hobbies and
exposures) may suggest exposure to endemic fungi (Histoplas-
ma capsulatum, Coccidioides immitis and Blastomyces dermatit-
idis) or unusual pathogens (e.g., Q fever, tularemia, psittacosis,
leptospirosis, etc.) [4], in this situation, radiological investiga-
tions in the form of CT chest thoracic ultrasound pulmonary
angiography or aortography may be enrolled in solving this
issue. Bronchoscopy, with appropriate cultures and appropri-
ate serologies, should be done. In other context, pulmonary
embolism, congestive heart failure, atelectasis, malignancies
and a host of immune mediated syndromes can masquerade
as pneumonia [8].
Distinguishing noninfectious causes of pulmonary inﬁl-
trates from infection may be difﬁcult. Noninfectious disorders
often present with a more indolent course, less striking clinical
presentation, and nonpurulent sputum or nonproductive
cough [9]. Routine laboratory tests do not discriminate pneu-
monia from disease attributable to noninfectious causes. Leu-
kocytosis may be present in diverse immune-mediated
disorders; conversely, leukocyte counts may be normal in
pneumonias caused by viruses, atypical agents, or bacteria [10].
Delayed resolution of pneumonia may reﬂect underlying
malignancy with or without endobronchial occlusion. Bron-
chogenic carcinoma should be suspected in patients with spe-
ciﬁc risk factors (e.g., smoking history, advanced age,hemoptysis, and absence of fever). Other malignancies may
present as focal alveolar opacities (mimicking pneumonia)
[12]. Bronchioloalveolar cell carcinomas [11] and primary pul-
monary lymphomas or lymphoproliferative disorders, occa-
sionally present with focal, alveolar lesions, hence lung
biopsies are required to substantiate the diagnosis [13]. Presen-
tation of lung cancer in the form of non-resolving pneumonia
is rather an atypical one and high index of suspicion is required
for its diagnosis, especially in the young [14].
Aim of work
Deﬁne to what extent early anticipation of underlying causes
of delayed resolving pneumonia via clinical, radiological and
bronchoscopic markers would modify management plan and
affect their outcomes.
Patients and methods
This prospective clinical study included 122 patients admitted
in the chest department, Mansoura University Hospital in the
period from June 2013 to August 2014 with delayed resolving
pneumonia beyond 2 weeks in spite of optimal antibiotic ther-
apy. They were divided according to ﬁnal diagnosis into two
groups:
Group I: included 58 patients diagnosed and known to be
of malignant etiology.
Group II: included 64 patients diagnosed and known to be
of non-malignant etiology.
Exclusion criteria: Patients with:
- Pneumonia before 2 weeks.
- Non compliant patients.
- Malignant lung from the start.
- Known to be immunocompromised from the start.
- Contraindication of biopsy procedure (bleeding diathesis).
Final diagnosis included pathological diagnosis by CT or
US guided biopsy thoracoscopic, bronchoscopic or open biop-
sies and patient follow up.
All cases were subjected to full history taking, clinical exam-
ination, routine laboratory investigations, ﬁberoptic bronchos-
copy and radiological investigation in the form of chest X-ray,
computed tomography CT chest and transthoracic ultrasound.
Clinical markers of malignancy according to Ferrer et al. [15]
were age more than 50 years, positive smoking history, absence
of fever, history of previous malignancy and duration of illness
>1 month. Bronchoscopic signs suggestive of malignancy
adopted in our study according to Tsaubi et al. [16] were four
types of tumor–bronchus relationships. First, if the bronchial
lumen is patent up to the tumor. Second, if the bronchus is con-
tained in the tumor mass. Third, if the bronchus is compressed
by the tumor with intact bronchial mucosa. Fourth, if the prox-
imal bronchial tree is narrowed by peribronchial or submucosal
spread of the tumor or by enlarged lymph nodes. Computed
Tomography (CT) markers suggestive of malignancy adopted
in this study according toArenas et al. [17] were pleural nodules,
pulmonary mass, mediastinal lymphadenopathy, chest wall
invasion, pleural nodular thickening >1 cm and pulmonary
cavity with shaggy irregular wall. Thoracic ultrasonographic
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Mathis [18] were ﬁrst, malignant morphology; irregular with
ramiﬁcation, second, uneven contour of the pleural surface with
irregular deformation due to invasion by a lung carcinoma,
third invasion of adjacent structures (chest wall, diaphragm
and pericardium), fourth, destruction of normal tissue architec-
ture, ﬁfth, heterogeneous hypoechogenicity and sixth, blood
vessel displacement, destruction and/or neovascularization by
Doppler ultrasound.
Statistical analysis
Data were analyzed using SPSS (Statistical Package for Social
Sciences) version 21. Qualitative data were presented as number
and percentage. Quantitative data were presented for normality
by the Kolmogorov–Smirnov test. Normally distributed data
were presented as mean and standard deviation. Comparison
between groups was done using the Chi-Square test. Student’s
t-test was used to compare two groups. P value <0.05 was con-
sidered signiﬁcant. Sensitivity, speciﬁcity and J index were calcu-
lated for each marker in addition to positive and negative
predicted values.Degree of agreement; kappa test; wasmeasured.Results
Table 1, shows that; our study was conducted on 122 patients
(86 males and 36 females) with a non-signiﬁcant statistical
difference between malignant and non-malignant groupsTable 2 Final diagnosis of the studied cases.
Malignant group (n= 58)
Small cell lung cancer 11 (18.96%)
Non small cell lung cancer 38 (65.5%)
Pulmonary metastasis 9 (15.5%)
Table 3 Clinical and bronchoscopic markers of malignancy in stud
Clinical and bronchoscopic markers of malignancy Malignant gr
Clinical markers
Age >50 years 41 (70.68%)
Smoking history 44 (75.86%)
Absence of fever 38 (65.5%)
History of previous malignancy 7 (12.1%)
Duration of illness >1 month 32 (55.17%)
Bronchoscopic markers of malignancy 7 (12.7%)
* Denotes a signiﬁcant value.
Table 1 Age, sex and smoking history in studied cases.
Malignant group
(n= 58)
Non-malignant
group (n= 64)
p Value
Age 53.03 ± 13.23 54.45 ± 13.48 0.875
Sex
Male 41 (70.6%) 45 (70.3%) 0.964
Female 17 (29.4%) 19 (29.6%)
Smoking
Non smoker 14 (24.13%) 23 (35.9%) 0.162
Smoker 44 (75.86%) 41 (64.1%)(p value = 0.964) regarding sex. The mean age was 53.89
± 14.50 years (range 15–85 years) in total studied cases. Mean
age of patients in the malignant group was 53.03 ± 13.23 years,
while it was 54.45 ± 13.48 years in the non-malignant group
with a non-signiﬁcant statistical difference.
As regards smoking history, thirty-seven cases were non
smoker, 85 cases were smokers and the malignant group
enrolled the highest percentage of smokers (75.86%), on the
contrary to the non-malignant group (64%), while non smok-
ers were higher in the non-malignant group than the malignant
one (35.9% versus 24.1% respectively) with a non-signiﬁcant
statistical difference. From previous data, both groups were
comparable to each other owing to the absence of signiﬁcant
statistical differences in age, sex and smoking history.
As shown in Table 2 the ﬁnal diagnostic results of the stud-
ied cases demonstrated that the malignant group included 11
cases (18.96%) with small cell lung cancer (SCLC) and 38 cases
(65.5%) with non small cell lung cancer (NSCLC) and 9 cases
with pulmonary metastasis (15.5%). On the other hand the
non-malignant group involved nonspeciﬁc pneumonia in 42
cases (65.63%) and 14 cases (21.86%) with speciﬁc forms of
pneumonia (tuberculous pneumonia in 9 cases, fungal in 4
cases and hydatid in one case). Pulmonary sequestration was
present in 4 cases and lastly traction bronchiectasis in 4 cases
(6.25% for each).
Table 3 shows that; clinical markers of malignancy were
prevalent in the malignant group than the non-malignant
one (70.68%, 75.86%, 65.5%, 12.1% and 55.17% respectively)
but with a non-signiﬁcant statistical difference between two
groups apart from duration of illness (p= 0.035). However;
endoscopic markers suggestive of malignancy were statistically
signiﬁcantly higher in the malignant group than the non-malig-
nant one (p value = 0.001).
Table 4 shows that; CT markers of malignancy which were
statistically signiﬁcantly higher in malignant than the non-
malignant groups were pulmonary mass (p 6 0.001), mediasti-
nal lymphadenopathy (p 6 0.001) and shaggy pulmonary
cavitation (p= 0.003). On the other side pleural nodules were
approximate in both groups while pleural nodular thickening
and chest wall invasion were absent in the non-malignant
group with non-signiﬁcant statistical differences.Non-malignant group (n= 64)
Non speciﬁc pneumonia 42 (65.63%)
Speciﬁc pneumonia 14 (21.86%)
Sequestration 4 (6.25%)
Localized traction bronchiectasis 4 (6.25%)
ied cases.
oup (n= 58) Non-malignant group (n= 64) p Value
32 (50%) 0.831
40 (62.5%) 0.147
23 (35.9%) 0.712
3 (4.6%) 0.942
12 (18.75%) 0.035*
0 (0%) 0.001*
Table 6 Statistical predictors of markers of malignancy in studied cases.
Test Sensitivity Speciﬁcity J index Accuracy Kappa PPV NPV
Clinical markers 72.36 20.62 8.95 62.08 0.077 46.63 48
CT chest markers 53.45 59.38 12.83 65.56 0.128 54.39 58.46
US markers 75.86 17.19 6.95 45.08 0.067 45.63 44
CT= computed tomography; US = ultrasound.
Table 4 CT chest markers of malignancy in studied cases.
CT chest markers of malignancy Malignant group (n= 58) Non-malignant group (n= 64) p Value
Invasion of chest wall 2 (3.6%) 0 (0%) 0.202
Pleural nodules 3 (5.2%) 5 (7.8%) 0.238
Nodular pleural thickening >1 cm 2 (3.12%) 0 (0%) 0.175
Pulmonary mass 47 (81.03%) 14 (21.87%) <0.001*
Shaggy pulmonary cavity 9 (14.06%) 0 (0%) 0.003*
Mediastinal lymphadenopathy 28 (48.3%) 6 (9.4%) <0.001*
* Denotes a signiﬁcant value.
Table 5 Transthoracic ultrasound markers of malignancy in studied cases.
Transthoracic ultrasound markers of malignancy Malignant group (n= 58) Non-malignant group (n= 64) p Value
Malignant morphology: irregular with ramiﬁcations 47 (81.03%) 12 (18.75) 0.021*
Heterogeneous hypoechogenicity 28 (48.27%) 13 (20.31%) 0.169
Echo invasion of surroundings 34 (58.62%) 13 (20.31%) 0.011*
Destruction of normal tissue architecture 34 (58.62%) 13 (20.31%) 0.011*
Displacement and destruction of blood vessels 34 (58.62%) 13 (20.31%) 0.011*
Irregular contour of the pleural surface 32 (58.62%) 13 (20.31%) 0.011*
* Denotes a signiﬁcant value.
Table 7 Discriminate analysis of all markers.
Predicted markers of grouping membership Total
Non-malignant Malignant
Final diagnosis, No. (%) Non-malignant 46 (71.8%) 18 (28.1%) 64
Malignant 19 (32.75%) 39 (67.2%) 58
69.7% of originally grouped cases correctly classiﬁed: (46 + 39/122).
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morphology with ramiﬁcations prevailed in the malignant
group with a statistical signiﬁcance (p= 0.021). Irregular
pleural contour echo invasion, destruction of normal tissue
architecture and blood vessel displacement were predominant
and more common in malignant than the non-malignant group
with a signiﬁcant statistical difference (p= 0.011). However;
there is no statistical signiﬁcant difference between both
groups in case of heterogeneous hypoechogenicity that was
more common in malignant than the non-malignant group.
As shown in Table 6; the sensitivity of clinical markers of
malignancy was higher than CT chest (72.36% and 53.45%
respectively) in the diagnosis of total studied cases. Neverthe-
less speciﬁcity of CT chest was higher than clinical (59.38%
and 20.62% respectively). On the other hand thoracic ultra-
sound showed the highest sensitivity (75.86%) but lowest spec-
iﬁcity (17.19%). Accuracy of these markers overweighed in CTchest (65.56%) followed by clinical (62.08%) then thoracic
ultrasound at last.
Table 7 shows that; summation of these four markers (clin-
ical, FOB, CT chest and sonographic) collectively increased
the probability of the diagnosis of malignancy in 67.2% of
cases diagnosed with malignancy and excluded malignancy in
71.8% of cases that were non-malignant with a success rate
of 69.7%.Discussion
Delayed resolving pneumonia is a diagnostic dilemma and
patients with this pulmonary event are usually subjected to
inappropriate invasive and costly investigations for its evalua-
tion. Multiple etiologies and outcomes including unpleasant
causes should be searched on and put in consideration. Hence
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clinical, radiological and bronchoscopic, or laboratory
although laboratory parameters are so many and need further
studies.
In our study, CT guided biopsy was done for 68 cases and
53 cases underwent US guided biopsy. Of the 122 cases, one
case was referred for open thoracotomy after negative CT
guided biopsy while thoracoscopic biopsy of another case
was done after negative US guided biopsy and one case refused
biopsy and follow up was considered in this case.
In accordance with Ferrer et al. [15] in our study, clinical
markers of malignancy (age >50 years, smoking history,
absence of fever, history of previous malignancy and duration
of illness >1 month) were prevalent in the malignant group
than the non-malignant one (70.68%, 75.86%, 65.5%, 12.1%
and 55.17% respectively) but with a non-signiﬁcant statistical
difference between both groups apart from duration of illness
which was signiﬁcantly higher in malignant than non-malig-
nant one (p= 0.035). Up to now, depending upon clinical fea-
tures signs and symptoms unaided to imply that the ﬁnal
diagnosis cannot be relied upon due to various overlapping
between diseases in addition to many atypical presentations
that confuse with other diagnosis. So, in our study insigniﬁ-
cance ascertains this concept and supports the role of thumb
that establishes clinical guidance and probability to direct
the pulmonologist to more precise investigations.
Similarly, Gurney et al. [19] conﬁrmed that speciﬁc clinical
features affect the likelihood of benignancy or malignancy,
however, in conjunction with imaging characteristics of the
lesion, both can impact the diagnostic approach and choice
of therapeutic options. The clinical factors to be considered
in evaluating the likelihood of malignancy in a peripheral pul-
monary lesion included patient age, smoking history; severe
pulmonary symptoms, comorbid conditions, history, type of
prior malignancy and environmental exposures.
Bronchogenic carcinoma has varied presentation. Uncom-
monly it may present mimicking pneumonia which may mask
the original disease and thus may delay the diagnosis. But
while considering the differential of a young individual pre-
senting with cough, fever, chest pain and the differential of a
malignancy being the cause is probably at the bottom of the
list of the ones considered [14].
Bronchoscopic ﬁndings were suggestive of malignancy
adopted in our study according to Tsaubi et al. criteria [16]
which showed that; 7 cases (12.7%) presented with positive
endoscopic ﬁndings suggestive of malignancy in the malignant
group (3 cases with endobronchial tumor mass, 3 cases with
bronchial wall compression and one case with bronchus con-
tained in the tumor) but they were absent in non-malignant
one, with a signiﬁcant statistical difference (p value = 0.001).
Although malignancy was known to have positive endoscopic
ﬁndings yet early malignancy and certain forms as consolida-
tions due to adenocarcinoma may present with lesions beyond
bronchoscopic view, hence other methods should be in hand
for diagnostic access. In a study done by Jayaprakash [2] ﬁbre-
optic bronchoscopy was done in 52 patients, malignant cells
were detected in 9 cases from FOB brushing/washing/biopsy.
Sputum cytology yielded malignant cells in 8 cases. M. tuber-
culosis culture was positive in 6 cases. Malignancy was the next
common cause in 19 (27%) of nonresolution. A diagnosis of
malignancy was made from tissue histopathology, sputum
cytology, bronchoscopy, lung FNAC, etc. In their study, theincidence of malignancy was very high compared to western
literature which shows malignancy in up to 11% of nonresolv-
ing cases however in our study the incidence of malignancy
was 47.54%. Bronchiolitis obliterans (5.7%) was diagnosed
on the basis of positive history, chest X-ray, HRCT
ﬁndings and the response to steroids. Pneumocystis carinii
(jirovecii) pneumonia 5(7.1%) was diagnosed by the typical
radiological ﬁndings, arterial PaO2 <70 mmHg in patients
who are HIV positive and the response to therapy. In our
patients, diagnosis of tuberculous pneumonia was based on
Ziehl–Neelsen staining of smear and Bactec tuberculous
culture of patient sputum or lavage, however fungal
infections depended on CT chest ﬁndings of mycetoma and
bronchoalveolar lavage culture.
In our study, CT markers of malignancy according to Are-
nas et al. [17] that were statistically signiﬁcantly higher in
malignant than the non-malignant group were pulmonary
mass (81.03% versus 21.87%) with p 6 0.001, mediastinal lym-
phadenopathy (48.3% versus 9.4%) with p 6 0.001 followed
by shaggy pulmonary cavitation (14.06% versus 0%) with
p= 0.003. On the other side pleural nodules were approximate
in both groups while pleural nodular thickening and chest wall
invasion were present in the malignant group only owing to
aggressive and advanced form of disease activity with non-sig-
niﬁcant statistical differences.
Likewise, ﬁndings suggestive of malignancy of consolidated
lesions by CT chest were studied by Auerbach and Garﬁnkel
[20] who stated that approximately 40% of bronchial carcino-
mas arose beyond the segmental bronchi and in 30% a periph-
eral mass was the sole radiographic ﬁnding. The majority of
peripheral lung cancers were approximately spherical or oval
in shape. Heitzman et al. [21] found that lobulation, cauli-
ﬂower appearances a sign that indicated uneven growth rates
in different parts of the tumor was highly suggestive of bron-
chial carcinoma.
In study done by Jayaprakash and Vipin [2] CT scan espe-
cially HRCT high resolution computed tomography was a use-
ful aid in reaching a diagnosis. Six cases of occult
bronchiectasis were diagnosed from HRCT. In tuberculosis,
a bilateral acinar pattern with cavitation (especially cavities
not made out in the chest X-ray), and bronchiolitis with tree
in bud appearance were helpful in the diagnosis. Lung carci-
noma was suspected when mass lesions, hilar adenopathy, col-
lapse with consolidation and chest wall involvement were
present. Lower zone lesions, mosaic perfusion on HRCT in
expiratory ﬁlms and nodules suggestive of bronchiolitis were
present in BOOP. Our cases of pulmonary sequestrations, trac-
tion bronchiectasis and hydatid disease were diagnosed on CT
radiological basis speciﬁc for each.
Mahoney et al. [22] and Grewal et al. [23] found that
peripheral lung cancers, notably adenocarcinoma and bron-
choalveolar carcinoma, had ill-deﬁned edges similar to pneu-
monic consolidation. Cavitation may be identiﬁed in tumors
of any size, walls of the cavitations were of irregular thickness
and may contain tumor nodules, but sometimes the wall had
smooth inner and outer margins. In our study we found that
shaggy pulmonary cavitation accounted for 14.06% in malig-
nant versus 0% in the non-malignant group due to secondary
changes by infections and necrosis of the tumor changing wall
outlines.
Zwirewich et al. [24] and Henschke et al. [25] reported that
the presence of chest wall invasion by CT chest adjacent to an
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unless there was a clear-cut bone destruction or a large soft tis-
sue mass. Contact with the pleura on CT examination, even if
the pleura was thickened did not necessarily indicate invasion,
though the greater the degree of contact and the greater the
pleural thickening, the more likely the parietal pleura had been
invaded. Bury et al. [26], Erasmus et al. [27] and Schafﬂer et al.
[28] conﬁrmed that pleural involvement may occur as a result
of direct spread, lymphatic involvement, or tumor emboli and
might be presented with pleural effusion in association with a
primary lung cancer in 91% of cases. In our cases chest wall
invasion was detected in the malignant group only (3.6%) with
nonsigniﬁcant statistical differences between both groups.
Pleural involvement presented nodules in the non-malignant
group due to tuberculous affection but nodular thickening
>1 cm presented in malignant one with a low percentage
and nonstatistical signiﬁcance leading to poor reliance upon
as radiological marker of malignancy.
In a similar way, mediastinal lymphadenopathy was
detected in 48.3% of malignant versus 9.4% in the non-malig-
nant group in our study population depending on standard
lymph node size of 1.5 cm. Tateishi et al. [29] demonstrated
that lung cancers usually extend to ipsilateral hilar nodes, ipsi-
lateral mediastinal, contralateral mediastinal and supraclavicu-
lar lymph nodes. Buy et al. [30] dedicated that a reasonable
generalization was that both sensitivity and speciﬁcity of
lymph node size were in the 50–60% range when the cut-off
point for normal was a short axis diameter of 1 cm.
The National Lung Screening Trial (NLST) [31] was a ran-
domized trial that compared screening by chest CT scanning
versus CT guided biopsy for three years in high risk persons.
Lung cancers detected by CT scanning were mostly 70% of
CT-cases by detecting lung nodule, pulmonary mass with
mediastinal lymphadenopathy and chest wall invasion. The
total success rate of CT chest was 54% in contrast to CT
guided biopsy that accounted for 88%. They matched with
total success rate of CT chest criteria in our study that was
53.45% in diagnosing malignancy.
In our study, it was noticed that; the clinical markers of
malignancy showed a higher sensitivity (72.36%) and lower
speciﬁcity (20.62%) and also US markers showed the highest
sensitivity (75.86%) but lowest speciﬁcity (17.19%). However,
CT chest markers showed a higher speciﬁcity (59.38%) and
lower sensitivity (53.45%). This means that there is no single
marker we can rely upon for prediction of malignancy in case
of delayed resolution of pneumonia.
We found that summation of these four markers (clinical,
FOB, CT chest and thoracic ultrasound) collectively increased
the probability of the diagnosis of malignancy in 67.2% of
cases diagnosed with malignancy and possibility to exclude
malignancy in 71.8% of cases that were non-malignant with
a success percentage of 69.7%.
Conclusion
Delayed resolving pneumonia every now and then over-
weighed the suspicion of obscure issue and awful background.
Early anticipation of what beyond delayed resolving pulmon-
ary consolidation can assist in dealing with the causes and
supervising the course and guard against the consequences.
To notarize either of clinical, radiological and bronchoscopicmarkers alone could not be relied upon to denote to the malig-
nant nature of the delayed pneumonic event but need collabo-
ration between all accessible predictors.Conﬂict of interest
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